Zoledronic acid in preventing fractures in women with postmenopausal osteoporosis: A meta analysis / 第二军医大学学报

ABSTRACT

Objective To systematically analyze the studies investigating the outcomes of once-yearly administered intravenous zoledronic acid for preventing postmenopausalosteoporosis fracture. Methods Cochrane' s systematic review methodswere used to retrieve the randomized controlled trials (RCT) about decreasing the risks of osteoporosis fracture in postmenopausalwomen by zoledronic acid from Cochrane Library, PubMed(Jan. 1966 to Apr. 2011), OVIDCJan. 1993 to Apr. 2011), EMBASECJan. 1974 to Apr. 2011), CNKI (Jan. 1979 to Apr. 2011), and VIP (Jan. 1989 to Apr. 2011) database. The studieswere limited to human studies including bone fracture rates and follow-up for 2-3 years. All literatures identified from the data sources were evaluated for review inclusion, and the methodology of the included literatures was evaluated. Meta-analysiswas performed using RevMan 5. 0. 25 software. Results Three randomized controlled studies met the inclusion criteria, including a total of 11 947 postmenopausal women with osteoporosis. Meta analysis results showed that zoledronic acid could reduce clinical vertebral fractures, hip fractures and nonvertebral-nonhip fractures by75% (RR = 0. 25, 95%CI 0.18-0.36), 33% (RR = 0. 67, 95%CI 0.52-0.85), and 24% (RR = 0.76, 95%CI 0.67-0. 87), respectively (P< 0. 05 for all comparisons). The incidence rates of serious adverse events were not significantly different between zoledronic acid groupand placebo group. Conclusion Once-yearly intravenous injection of zoledronic acid (5 mg) can effectively prevent osteoporosis fracture in postmenopausal women without increasing the risk of serious adverse events.